A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer
2026年6月11日 更新者:GlaxoSmithKline
Phase 4, Open Label, Single-arm, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Primary Advanced or Recurrent Endometrial Cancer
This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).
研究概览
研究类型
介入性
注册 (估计的)
100
阶段
- 第四阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
研究联系人备份
- 姓名:EU GSK Clinical Trials Call Center
- 电话号码:+44 (0) 20 89904466
- 邮箱:GSKClinicalSupportHD@gsk.com
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Participant with greater than or equals to (>=) 18 years of age, at the time of signing the informed consent.
- Participant has histologically or cytologically proven EC with recurrent or advanced disease.
- Participant must have primary Stage III or Stage IV disease or first recurrent EC with a low potential for cure by radiation therapy or surgery alone or in combination based on investigator's assessment.
- Eligible for dostarlimab treatment according to the approved prescribing information and the investigator's clinical judgement.
- Woman of childbearing potential (WOCBP) agrees to use contraceptive from screening through at least 180 days after the last dose.
- Negative urine pregnancy test at most 24 hours prior to the first dose of study intervention.
- Capable of giving signed informed consent.
- Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
- Participant has had greater than (>) 1 recurrence of endometrial cancer.
- Participant has a concomitant malignancy, or participant has a prior non endometrial invasive malignancy who has been disease-free for less than (<) 3 years or who received any active treatment in the last 3 years for that malignancy.
- Participant has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.
- Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy.
- Participant has not recovered adequately from AEs or complications from any major surgery prior to starting therapy.
- Participant has not recovered (i.e., to Grade less than or equal to [<=] 1 or to Baseline) from cytotoxic therapy induced AEs or has received transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony-stimulating factor [G-CSF], Granulocyte macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 21 days prior to the first dose of study drug.
- Either the history of hypersensitivity to excipients of the study intervention or to drugs with a similar chemical structure or class of the study intervention.
- Participant has known active hepatitis B (e.g., hepatitis B surface antigen reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid [qualitative] is detected).
Participant has received neo-adjuvant/adjuvant systemic anticancer therapy for primary Stage III or IV disease and:
- has not had a recurrence or Progressive disease (PD) prior to first dose on the study, or
- has had a recurrence or PD within 6 months of completing systemic anticancer therapy treatment prior to first dose on the study.
- Participant has received prior therapy with an anti- Programmed death protein 1 (anti-PD-1), anti- Programmed death ligand 1 (anti-PD-L1), or Programmed death ligand 2 (anti PD L2) agent.
- Participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days or <5 times the half life of the most recent therapy prior to study Day 1, whichever is shorter.
- Systemic glucocorticoids for any purpose other than to manage symptoms of suspected irAEs. If medically deemed necessary (e.g., acute asthma or chronic obstructive pulmonary disease exacerbation, prophylaxis for intravenous (IV) contrast if indicated), Investigators are allowed to use their judgment to treat participants with systemic steroids. In such cases, systemic steroids should be stopped at least 24 hours prior to the next dose of study treatment.
- Participant has received, or is scheduled to receive, a live vaccine within 30 days before first dose of study intervention, during study treatment, and for up to 180 days after receiving the last dose of study intervention.
- Participant has a diagnosis of immunodeficiency and is receiving systemic steroid therapy (>10 milligrams [mg] daily prednisone or equivalent) within 7 days prior to the first dose of the study treatment or is receiving any other form of immunosuppressive medication.
- Participant is currently receiving study intervention, or is enrolled or has participated in any other clinical study involving an investigational intervention and received investigational treatment or used an investigational device within 4 weeks of the first dose of dostarlimab.
- Participant is pregnant or breastfeeding or is expecting to conceive children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of study intervention.
- Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Participants receiving Dostarlimab with Carboplatin + Paclitaxel followed by Dostarlimab Monotherapy
Participants will receive dose level 1 of dostarlimab in combination with carboplatin and paclitaxel followed by dose level 2 of dostarlimab monotherapy.
Dose level 1 is the lowest dose level.
|
将使用 Dostarlimab。
将施用卡铂。
紫杉醇将进行管理。
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Number of participants with Grade 3 or greater treatment-emergent adverse events (TEAEs) up to Week 49
大体时间:Up to Week 49
|
Up to Week 49
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Number of participants with Grade 3 or greater TEAEs up to Week 170
大体时间:Up to Week 170
|
Up to Week 170
|
|
Number of participants with TEAEs up to Week 49
大体时间:Up to Week 49
|
Up to Week 49
|
|
Number of participants with TEAEs up to Week 170
大体时间:Up to Week 170
|
Up to Week 170
|
|
Number of participants with Immune-related adverse events (irAEs) up to Week 49
大体时间:Up to Week 49
|
Up to Week 49
|
|
Number of participants with Immune-related adverse events (irAEs) up to Week 170
大体时间:Up to Week 170
|
Up to Week 170
|
|
Number of Participants with Serious Adverse Events (SAEs), treatment related Adverse Events (AEs), treatment related SAEs, fatal AEs, non-fatal SAEs up to Week 49
大体时间:Up to Week 49
|
Up to Week 49
|
|
Number of Participants with Serious Adverse Events (SAEs), treatment related Adverse Events (AEs), treatment related SAEs, fatal AEs, non-fatal SAEs up to Week 170
大体时间:Up to Week 170
|
Up to Week 170
|
|
Number of Participants with AEs leading to discontinuation of treatment, AEs leading to study withdrawal and AEs leading to dose modification up to Week 49
大体时间:Up to Week 49
|
Up to Week 49
|
|
Number of Participants with AEs leading to discontinuation of treatment, AEs leading to study withdrawal and AEs leading to dose modification up to Week 170
大体时间:Up to Week 170
|
Up to Week 170
|
|
Change from Baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count (Giga cells per Liter) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count (Giga cells per Liter) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per Liter) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per Liter) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in hematology parameter: Hemoglobin (Hb) (Grams per Liter) up to Week 49
大体时间:Baseline (Day 1) and up to 49
|
Baseline (Day 1) and up to 49
|
|
Change from Baseline in hematology parameter: Hemoglobin (Hb) (Grams per Liter) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in hematology parameter: Reticulocytes (Percentage of reticulocytes) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in hematology parameter: Reticulocytes (Percentage of reticulocytes) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters) to up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in clinical chemistry parameters: Blood urea nitrogen (BUN), glucose, calcium, sodium, and potassium levels (Millimoles per Liter) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in clinical chemistry parameters: Blood urea nitrogen (BUN), glucose, calcium, sodium, and potassium levels (Millimoles per Liter) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per Liter) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per Liter) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in clinical chemistry parameters: Total protein levels (Gram per liter) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in clinical chemistry parameters: Total protein levels (Gram per liter) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels (International units per liter) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels (International units per liter) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in Vital signs: systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg]) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in Vital signs: systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg]) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in Vital signs: pulse rate (Beats per minute) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in Vital signs: pulse rate (Beats per minute) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in Vital signs: body temperature (Degrees Celsius) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in Vital signs: body temperature (Degrees Celsius) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in Vital signs: respiratory rate (breaths per minute) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in Vital signs: respiratory rate (breaths per minute) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in electrocardiogram (ECG) values: Heart rate (Beats per minute) up to Week 49
大体时间:Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in electrocardiogram (ECG) values: Heart rate (Beats per minute) up to Week 170
大体时间:Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 研究主任:GSK Clinical Trials、GlaxoSmithKline
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年8月17日
初级完成 (估计的)
2030年8月30日
研究完成 (估计的)
2030年8月30日
研究注册日期
首次提交
2026年6月11日
首先提交符合 QC 标准的
2026年6月11日
首次发布 (实际的)
2026年6月17日
研究记录更新
最后更新发布 (实际的)
2026年6月17日
上次提交的符合 QC 标准的更新
2026年6月11日
最后验证
2026年6月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 309169
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
是的
IPD 计划说明
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents.
Data sharing is subject to certain criteria, conditions, and exceptions.
For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD 共享时间框架
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD 共享访问标准
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
是的
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.